The AffloVest is battery-operated and uses Direct Dynamic Oscillation technology, which closely mimics hand CPT (Chest Physical Therapy) to help mobilise and clear secretions from the lungs, and allows for full freedom of mobility during treatment.
Doctors prescribe AffloVest for patients across a range of ages who have severe respiratory diseases such as bronchiectasis, cystic fibrosis, and certain neuromuscular diseases.
This next generation AffloVest, which began shipping September 1, is much lighter, quieter, and more efficient, with a smaller profile battery and long-life, state-of-the-art motors, offering improved patient ease of use.
The new AffloVest is on average 2 pounds lighter (more than 20% less weight) than the previous version, and uses streamlined components and tailored styling for a sleeker, slimmer fit.
International Biophysics brings to market medical devices and technologies aimed at improving treatment therapies and patient outcomes.
The company's precision ISO 13485 certified, FDA registered, quality controlled US manufacturing facility is located in Austin, Texas.
IDEAYA Biosciences submits IND for IDE892; Targets Phase 1 in 4Q 2025
Airiver medical receives FDA approval for central airway stenosis trial
INOVIO to begin rolling submission of BLA for INO-3107
Calluna Pharma begins Phase 2 study of CAL101 in idiopathic pulmonary fibrosis
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Innovent Biologics receives approval over squamous cell lung cancer study
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
HUTCHMED completes enrollment in Phase III SANOVO trial of ORPATHYS and TAGRISSO in China
LivaNova announces commercial launch of Essenz Perfusion System in China
Precigen's PAPZIMEOS granted US FDA approval to treat with recurrent respiratory papillomatosis
Leads Biolabs completes patient enrollment in pivotal Opamtistomig trial for EP-NEC
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation